Vivos Therapeutics Inc.
Organization details
- Legal name
- Vivos Therapeutics Inc.
- Former names
- Vivos BioTechnologies, Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 3841 — Surgical & Medical Instruments & Apparatus
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Littleton
- Headquarters state / province
- Colorado
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- VVOS
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001716166
- EIN
- 81-3224056
Board of directors
-
Anja B. Krammer · DirectorSince 2024
-
Gregg C. Johnson · DirectorSince 2026
-
Leonard J. Sokolow · DirectorSince 2024
-
Mark F. Lindsay · DirectorSince 2024
-
Matthew Thompson · DirectorSince 2024
-
Ralph Elias Green · DirectorSince 2024
-
Ronald Kirk Huntsman · Director · Chief Executive OfficerSince 2023
Chief executives
Director election results
Annual meeting of November 4, 2025. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
88.4%
-
89.6%
-
90.9%
-
92.2%
-
93.0%
-
93.6%
Board connections
2 of this board's directors also sit on 4 other boards.
- via Leonard J. Sokolow
- via Leonard J. Sokolow
- via Leonard J. Sokolow
- via Gregg C. Johnson
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $1,813,858
- 2 purchases by 1 insider
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 31, 2026 | Amman Bradford K. Officer (Principal Accounting Officer) | Grant or award | +250,000 | $0.41 | $102,500 |
| Jun 30, 2026 | Ronald Kirk Huntsman Director, Officer (Chief Executive Officer) | Other | +85,910 | $0.58 | $49,828 |
| Mar 31, 2026 | V-Co Investors 3 LLC 10% owner | Open-market purchase | +1,044,777 | $1.34 | $1,400,001 |
| Mar 31, 2026 | V-Co Investors 3 LLC 10% owner | Open-market purchase | +308,848 | $1.34 | $413,856 |
| Jun 20, 2023 | Ronald Kirk Huntsman Director, Officer (Chief Executive Officer) | Open-market purchase | +14,000 | $0.53 | $7,420 |
| Jun 16, 2023 | Ronald Kirk Huntsman Director, Officer (Chief Executive Officer) | Open-market purchase | +10,000 | $0.54 | $5,400 |
| Jun 16, 2023 | Ronald Kirk Huntsman Director, Officer (Chief Executive Officer) | Open-market purchase | +5,000 | $0.53 | $2,650 |
| Jun 15, 2023 | Ronald Kirk Huntsman Director, Officer (Chief Executive Officer) | Open-market purchase | +21 | $0.50 | $11 |
| Jun 14, 2023 | Ronald Kirk Huntsman Director, Officer (Chief Executive Officer) | Open-market purchase | +10,000 | $0.49 | $4,900 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Vivos Therapeutics Inc.
Who is the CEO of Vivos Therapeutics Inc.?
Ronald Kirk Huntsman is Vivos Therapeutics Inc.'s Chief Executive Officer.
How many directors are on Vivos Therapeutics Inc.'s board?
Vivos Therapeutics Inc.'s board has 7 directors: Anja B. Krammer, Gregg C. Johnson, Leonard J. Sokolow, Mark F. Lindsay, Matthew Thompson, Ralph Elias Green and Ronald Kirk Huntsman.
Are Vivos Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Vivos Therapeutics Inc. insiders bought $1.8 million of shares in 2 purchases and made no open-market sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="vivos-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.